An Expanded Access Protocol for a Single Subject Who Has Completed 24-Weeks of Treatment in PR0140_CD02 Study (CD02_EA)
An Expanded Compassionate Access Protocol for a Single Subject Who Has Completed 24-Weeks of Treatment in PRO140_CD02 Study
Sponsor: Amarex Clinical Research
Listed as NCT02759042, this observational or N/A phase trial focuses on HIV and remains ongoing. Sponsored by Amarex Clinical Research, it has been updated 8 times since 2026, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
No Longer Available
-
Jul 2024 — Sep 2024 [monthly]
No Longer Available
-
Jan 2021 — Jul 2024 [monthly]
No Longer Available
-
Jun 2018 — Jan 2021 [monthly]
No Longer Available
-
Apr 2018 — Jun 2018 [monthly]
No Longer Available
Phase: NA → None
▶ Show 3 earlier versions
-
Sep 2017 — Apr 2018 [monthly]
No Longer Available NA
Status: Temporarily Not Available → No Longer Available
-
Feb 2017 — Sep 2017 [monthly]
Temporarily Not Available NA
-
Jan 2017 — Feb 2017 [monthly]
Temporarily Not Available NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Amarex Clinical Research
- CytoDyn, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .